Skip to main content

Advertisement

SpringerLink
Log in

Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C

  • Review
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Hepatitis C virus (HCV) is a single-stranded RNA virus known for its high genetic variability owing to the lack of a proofreading mechanism of its RNA dependent RNA polymerase. Until now, numerous studies have been undertaken to clarify the correlation between pretreatment HCV genetic variability and the therapeutic response. Even with the recent combination therapy of peginterferon plus ribavirin for chronic hepatitis C, viral response is variable, and only half of treated patients could clear the virus [sustained viral response (SVR)]. In this review, the contribution of viral genetic variability affecting the treatment outcome is discussed according to each HCV genomic region.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol. 2008;5(11):610–22.

    Article  PubMed  CAS  Google Scholar 

  2. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA. 1991;88(8):3392–6.

    Article  PubMed  CAS  Google Scholar 

  3. Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, et al. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology. 1992;190(2):894–9.

    Article  PubMed  CAS  Google Scholar 

  4. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42(4):962–73.

    Article  PubMed  CAS  Google Scholar 

  5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–82.

    Article  PubMed  CAS  Google Scholar 

  6. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–55.

    PubMed  CAS  Google Scholar 

  7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–65.

    Article  PubMed  CAS  Google Scholar 

  8. Dalgard O, Mangia A. Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. Drugs. 2006;66(14):1807–15.

    Article  PubMed  CAS  Google Scholar 

  9. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40 kDa) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129(2):522–7.

    Google Scholar 

  10. El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol. 2005;100(11):2447–52.

    Article  PubMed  CAS  Google Scholar 

  11. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005;54(6):858–66.

    Article  PubMed  CAS  Google Scholar 

  12. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol. 2005;3(10 Suppl 2):S97–101.

    Article  PubMed  CAS  Google Scholar 

  13. Araujo FM, Sonoda IV, Rodrigues NB, Teixeira R, Redondo RA, Oliveira GC. Genetic variability in the 5’ UTR and NS5A regions of hepatitis C virus RNA isolated from non-responding and responding patients with chronic HCV genotype 1 infection. Mem Inst Oswaldo Cruz. 2008;103(6):611–4.

    PubMed  Google Scholar 

  14. El Awady MK, Azzazy HM, Fahmy AM, Shawky SM, Badreldin NG, Yossef SS, et al. Positional effect of mutations in 5’UTR of hepatitis C virus 4a on patients’ response to therapy. World J Gastroenterol. 2009;15(12):1480–6.

    Article  PubMed  CAS  Google Scholar 

  15. Katano Y, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, et al. Association with 5’-untranslated region and response to interferon in chronic hepatitis C. Hepatogastroenterology. 2007;54(75):854–7.

    PubMed  CAS  Google Scholar 

  16. Soler M, Pellerin M, Malnou CE, Dhumeaux D, Kean KM, Pawlotsky JM. Quasi species heterogeneity and constraints on the evolution of the 5′ noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy. Virology. 2002;298(1):160–73.

    Article  PubMed  CAS  Google Scholar 

  17. Thelu MA, Drouet E, Hilleret MN, Zarski JP. Lack of clinical significance of variability in the internal ribosome entry site of hepatitis C virus. J Med Virol. 2004;72(3):396–405.

    Article  PubMed  CAS  Google Scholar 

  18. Yamamoto C, Enomoto N, Kurosaki M, Yu SH, Tazawa J, Izumi N, et al. Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus-1b: no association with efficacy of interferon therapy or serum HCV-RNA levels. Hepatology. 1997;26(6):1616–20.

    Article  PubMed  CAS  Google Scholar 

  19. Kountouras J, Zavos C, Chatzopoulos D. Apoptosis in hepatitis C. J Viral Hepat. 2003;10(5):335–42.

    Article  PubMed  CAS  Google Scholar 

  20. Hahn YS. Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Curr Opin Immunol. 2003;15(4):443–9.

    Article  PubMed  CAS  Google Scholar 

  21. Wang T, Weinman SA. Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C. J Gastroenterol Hepatol. 2006;21(Suppl 3):S34–7.

    Article  PubMed  CAS  Google Scholar 

  22. Mori Y, Moriishi K, Matsuura Y. Hepatitis C virus core protein: its coordinate roles with PA28gamma in metabolic abnormality and carcinogenicity in the liver. Int J Biochem Cell Biol. 2008;40(8):1437–42.

    Article  PubMed  CAS  Google Scholar 

  23. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009;29(Suppl 2):13–25.

    Article  PubMed  CAS  Google Scholar 

  24. Pazienza V, Clement S, Pugnale P, Conzelman S, Foti M, Mangia A, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology. 2007;45(5):1164–71.

    Article  PubMed  CAS  Google Scholar 

  25. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon–ribavirin combination therapy. Intervirology. 2005;48(6):372–80.

    Article  PubMed  CAS  Google Scholar 

  26. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol. 2009;81(3):452–8.

    Article  PubMed  CAS  Google Scholar 

  27. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2007;79(11):1686–95.

    Article  PubMed  CAS  Google Scholar 

  28. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007;46(3):403–10.

    Article  PubMed  CAS  Google Scholar 

  29. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology. 2007;46(5):1357–64.

    Article  PubMed  CAS  Google Scholar 

  30. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. J Med Virol. 2008;80(8):1354–62.

    Article  PubMed  CAS  Google Scholar 

  31. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol. 2007;81(15):8211–24.

    Article  PubMed  CAS  Google Scholar 

  32. Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, et al. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J Med Virol. 2009;81(4):640–9.

    Article  PubMed  CAS  Google Scholar 

  33. Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009;11 [Epub ahead of print].

  34. Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, et al. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol. 2008;82(24):12020–9.

    Article  PubMed  CAS  Google Scholar 

  35. Benedicto I, Molina-Jimenez F, Barreiro O, Maldonado-Rodriguez A, Prieto J, Moreno-Otero R, et al. Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology. 2008;48(4):1044–53.

    Article  PubMed  CAS  Google Scholar 

  36. Pavio N, Taylor DR, Lai MM. Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. J Virol. 2002;76(3):1265–72.

    PubMed  CAS  Google Scholar 

  37. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 1999;285(5424):107–10.

    Article  PubMed  CAS  Google Scholar 

  38. Taylor DR, Tian B, Romano PR, Hinnebusch AG, Lai MM, Mathews MB. Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain. J Virol. 2001;75(3):1265–73.

    Article  PubMed  CAS  Google Scholar 

  39. Gupta R, Subramani M, Khaja MN, Madhavi C, Roy S, Habibullah CM, et al. Analysis of mutations within the 5′ untranslated region, interferon sensitivity region, and PePHD region as a function of response to interferon therapy in hepatitis C virus-infected patients in India. J Clin Microbiol. 2006;44(3):709–15.

    Article  PubMed  CAS  Google Scholar 

  40. Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A, et al. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b. Am J Gastroenterol. 2003;98(6):1377–83.

    Article  PubMed  CAS  Google Scholar 

  41. Sarrazin C, Bruckner M, Herrmann E, Ruster B, Bruch K, Roth WK, et al. Quasi species heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. Virology. 2001;289(1):150–63.

    Article  PubMed  CAS  Google Scholar 

  42. Sarrazin C, Kornetzky I, Ruster B, Lee JH, Kronenberger B, Bruch K, et al. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. Hepatology. 2000;31(6):1360–70.

    Article  PubMed  CAS  Google Scholar 

  43. Gaudy C, Lambele M, Moreau A, Veillon P, Lunel F, Goudeau A. Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome. J Clin Microbiol. 2005;43(2):750–4.

    Article  PubMed  CAS  Google Scholar 

  44. Hung CH, Lee CM, Lu SN, Lee JF, Wang JH, Tung HD, et al. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat. 2003;10(2):87–94.

    Article  PubMed  Google Scholar 

  45. Munoz de Rueda P, Casado J, Paton R, Quintero D, Palacios A, Gila A, et al. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol. 2008;82(13):6644–53.

    Article  PubMed  CAS  Google Scholar 

  46. Murphy MD, Rosen HR, Marousek GI, Chou S. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci. 2002;47(6):1195–205.

    Article  PubMed  CAS  Google Scholar 

  47. Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, Vieux C, et al. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon–ribavirin therapy. J Med Virol. 2004;74(1):41–53.

    Article  PubMed  CAS  Google Scholar 

  48. Yang SS, Lai MY, Chen DS, Chen GH, Kao JH. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. Liver Int. 2003;23(6):426–33.

    Article  PubMed  CAS  Google Scholar 

  49. Yoon J, Lee JI, Baik SK, Lee KH, Sohn JH, Lee HW, et al. Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol. 2007;13(46):6236–42.

    Article  PubMed  CAS  Google Scholar 

  50. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest. 1995;96(1):224–30.

    Article  PubMed  CAS  Google Scholar 

  51. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334(2):77–81.

    Article  PubMed  CAS  Google Scholar 

  52. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology. 1997;25(3):745–9.

    Article  PubMed  CAS  Google Scholar 

  53. Komatsu H, Fujisawa T, Inui A, Miyagawa Y, Onoue M. Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitis C virus 1b infection. J Med Virol. 1997;53(4):361–5.

    Article  PubMed  CAS  Google Scholar 

  54. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, et al. Analysis of genotypes and amino acid residues 2209–2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology. 1997;25(3):750–3.

    Article  PubMed  CAS  Google Scholar 

  55. Chung RT, Monto A, Dienstag JL, Kaplan LM. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. J Med Virol. 1999;58(4):353–8.

    Article  PubMed  CAS  Google Scholar 

  56. Hofgartner WT, Polyak SJ, Sullivan DG, Carithers RL Jr, Gretch DR. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol. 1997;53(2):118–26.

    Article  PubMed  CAS  Google Scholar 

  57. Khorsi H, Castelain S, Wyseur A, Izopet J, Canva V, Rombout A, et al. Mutations of hepatitis C virus 1b NS5A 2209–2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol. 1997;27(1):72–7.

    Article  PubMed  CAS  Google Scholar 

  58. Odeberg J, Yun Z, Sonnerborg A, Weiland O, Lundeberg J. Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment. J Med Virol. 1998;56(1):33–8.

    Article  PubMed  CAS  Google Scholar 

  59. Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology. 1997;113(2):567–72.

    Article  PubMed  CAS  Google Scholar 

  60. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alpha. Hepatology. 1997;25(3):740–4.

    Article  PubMed  CAS  Google Scholar 

  61. Pascu M, Martus P, Hohne M, Wiedenmann B, Hopf U, Schreier E, et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut. 2004;53(9):1345–51.

    Article  PubMed  CAS  Google Scholar 

  62. Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasi species mutations. J Virol. 1998;72(4):2795–805.

    PubMed  CAS  Google Scholar 

  63. Saiz JC, Lopez-Labrador FX, Ampurdanes S, Dopazo J, Forns X, Sanchez-Tapias JM, et al. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J Infect Dis. 1998;177(4):839–47.

    PubMed  CAS  Google Scholar 

  64. Sarrazin C, Berg T, Lee JH, Ruster B, Kronenberger B, Roth WK, et al. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. J Infect Dis. 2000;181(2):432–41.

    Article  PubMed  CAS  Google Scholar 

  65. Sarrazin C, Berg T, Lee JH, Teuber G, Dietrich CF, Roth WK, et al. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol. 1999;30(6):1004–13.

    Article  PubMed  CAS  Google Scholar 

  66. Witherell GW, Beineke P. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol. 2001;63(1):8–16.

    Article  PubMed  CAS  Google Scholar 

  67. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology. 2008;48(6):1753–60.

    Article  PubMed  CAS  Google Scholar 

  68. Veillon P, Payan C, Le Guillou-Guillemette H, Gaudy C, Lunel F. Quasi species evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon–ribavirin therapy. World J Gastroenterol. 2007;13(8):1195–203.

    PubMed  CAS  Google Scholar 

  69. Yen YH, Hung CH, Hu TH, Chen CH, Wu CM, Wang JH, et al. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209–2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. Aliment Pharmacol Ther. 2008;27(1):72–9.

    Article  PubMed  CAS  Google Scholar 

  70. Gale MJ Jr, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 1997;230(2):217–27.

    Article  PubMed  CAS  Google Scholar 

  71. Inchauspe G, Zebedee S, Lee DH, Sugitani M, Nasoff M, Prince AM. Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc Natl Acad Sci USA. 1991;88(22):10292–6.

    Article  PubMed  CAS  Google Scholar 

  72. Duverlie G, Khorsi H, Castelain S, Jaillon O, Izopet J, Lunel F, et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol. 1998;79(Pt 6):1373–81.

    PubMed  CAS  Google Scholar 

  73. Puig-Basagoiti F, Forns X, Furcic I, Ampurdanes S, Gimenez-Barcons M, Franco S, et al. Dynamics of hepatitis C virus NS5A quasi species during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J Gen Virol. 2005;86(Pt 4):1067–75.

    Article  PubMed  CAS  Google Scholar 

  74. Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol. 2002;76(21):11079–90.

    Article  PubMed  CAS  Google Scholar 

  75. El-Shamy A, Sasayama M, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, et al. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera. Microbiol Immunol. 2007;51(4):471–82.

    PubMed  CAS  Google Scholar 

  76. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology. 2008;48(1):38–47.

    Article  PubMed  CAS  Google Scholar 

  77. Pfeiffer JK, Kirkegaard K. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol. 2005;79(4):2346–55.

    Article  PubMed  CAS  Google Scholar 

  78. Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, Milstein SL, et al. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology. 2003;38(4):869–78.

    PubMed  CAS  Google Scholar 

  79. Sugihara K, Orito E, Tanaka Y, Kato T, Lau JY, Ohno T, et al. Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy. Intervirology. 2006;49(6):319–26.

    Article  PubMed  CAS  Google Scholar 

  80. Ward CL, Dev A, Rigby S, Symonds WT, Patel K, Zekry A, et al. Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. J Viral Hepat. 2008 [Epub ahead of print].

  81. Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, Kurosaki M, et al. Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. J Gastroenterol Hepatol. 2005;20(9):1401–9.

    Article  PubMed  CAS  Google Scholar 

  82. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol. 2005;43(4):623–9.

    Article  PubMed  CAS  Google Scholar 

  83. Lutchman G, Danehower S, Song BC, Liang TJ, Hoofnagle JH, Thomson M, et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology. 2007;132(5):1757–66.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan

    Shinya Maekawa & Nobuyuki Enomoto

Authors
  1. Shinya Maekawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nobuyuki Enomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nobuyuki Enomoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maekawa, S., Enomoto, N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol 44, 1009–1015 (2009). https://doi.org/10.1007/s00535-009-0126-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-009-0126-7

Keywords

Search

Navigation